argenx SE ARGX NASDAQ

argenx SE (ARGX) reported total assets of $8.68B and total liabilities of $1.36B for fiscal year 2025, resulting in total equity of $7.32B.

The company held $4.44B in cash and short-term investments. Total debt stood at $83.49M, with net debt of $-3.41B. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 5.23, indicating strong short-term liquidity. Interest coverage is 237.5x (strong).

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.01, current ratio of 5.23, interest coverage 237.5x — balance sheet is strong
• MOAT (71/100) — Total assets $8.68B and equity $7.32B support the company's competitive scale
• VALUE (52/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.

ALNY

Alnylam Pharmaceuticals, Inc.

$339.41

+1.92%

SGEN

Seagen Inc.

$228.74

-0.07%

BGNE

BeiGene, Ltd.

$184.71

+0.49%

ASND

Ascendis Pharma A/S

$249.84

+0.52%

KRTX

Karuna Therapeutics, Inc.

$329.83

+0.03%

PCVX

Vaxcyte, Inc.

$62.76

+1.64%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

ISEE

IVERIC bio, Inc.

$39.95

+0.38%